Background
There is a renewed interest in the use of natural compounds to prevent/treat several types of diseases including cancer and inflammatory conditions [
1,
2]. Currently, there are more than 200 natural product-derived drugs already in preclinical/clinical development or in the clinic [
1,
3,
4]. The therapeutic properties of medicinal plants are generally attributed to plant secondary metabolites, an example of which are sesquiterpene lactones (SL), which are present almost exclusively in plant species belonging to the family
Asteraceae[
5,
6]. This family comprises plant species commonly used in ethnomedicine [
7], some of which have been reported to specifically treat diseases such as cancer, inflammation, headaches, and infections [
6,
8]. Sesquiterpene lactones often colorless and with a bitter taste, are a stable form of terpenoids and are divided into four groups: germacranolides, eudesmanolides, guaianolides, and pseudoguaianolides [
6]. The bioactivity of a SL molecule has been attributed to several factors including the number of alkylating centers, the lipophilicity of the molecule, and its geometry [
9]. Importantly, several SL-derived drugs are currently being tested in cancer clinical trials [
9].
Following bioassay guided fractionation, we have isolated, identified, and characterized two SL molecules of the guaianolide group, 3-β-methoxy-iso-seco-tanapartholide (β-tan) and salograviolide A (Sal A), with promising anti-tumor and anti-inflammatory activities [
10‐
14].
β-tan which was purified from
Achillea falcata, a species native to Lebanon and the Middle East [
15], differentially inhibited the growth of the epidermal human HaCaT cells at non-cytotoxic concentrations to primary epidermal keratinocytes [
11]. Sal A, which was isolated from
Centaurea ainetensis, also a species native to Lebanon and the Middle East, was found to possess anti-inflammatory [
13,
14,
16] and anti-cancer activities in a mouse colon cancer model and in skin cancer cells at different stages of tumorigenesis [
10,
12,
17].
In this study, we specifically investigated whether these SL molecules target the tumor promotion stage of tumorigenesis and cell transformation using the well-established JB6 mouse epidermal cell system, which includes the promotion-sensitive P + cells [
18,
19]. In contrast to tumor initiation, tumor promotion is largely reversible, dependent on epigenetic mechanisms, and is a rate-limiting step in multi-stage carcinogenesis, making it an attractive target for anticancer drugs [
20,
21]. The JB6P + cells can be transformed to malignancy by tumor promoters, and hence, constitute an ideal model to identify anti-tumor promoting and chemopreventive agents and to decipher their mechanism of action [
19,
22‐
24].
The anti-tumor promoting activities of β-tan and Sal A and their modulation of AP-1 and NF-κB signaling were investigated using JB6P + cells. AP-1 and NF-κB signaling pathways have been shown to be up regulated and to play key roles in tumor promotion and epidermal tumorigenesis [
19,
25]. Members of the AP-1 and NF-κB complexes are expressed at high levels in JB6P + cells [
19], and AP-1 and NF-κB activities are required for tumor promotion [
26,
27]. The inhibition of NF-κB and/or AP-1 activities abrogates transformation in JB6 cells in transgenic mice and in human keratinocytes [
25,
28‐
30].
Discussion
In this study, we investigated the anti-tumor promoting effects of β-tan and Sal A, isolated from
Achillea falcata and
Centaurea ainetensis, respectively, using the JB6 epidermal cell model of tumor promotion and cell transformation. In the multi-stage model of carcinogenesis, the tumor promotion phase is a rate limiting step that is responsible for the clonal expansion of initiated cells and is largely reversible [
41], offering a practical approach for identifying potential inhibitors of cancer development [
42].
Herein, we report that treatment with either Sal A or β-tan preferentially inhibited the growth of murine neoplastic keratinocytes, whilst sparing normal cells. The promotion-sensitive JB6P + cells were the most sensitive to β-tan treatment at concentrations that did not affect the growth of PMKs. Treatment with Sal A was relatively less potent on JB6P + cells, compared to β-tan, where 10 μg/ml β-tan inhibited cell growth by 74 ± 7%, whereas 10 μg/ml Sal A inhibited by 51 ± 4%. Although both belong to the SL guaianolide family, it seems that β-tan, with its relatively open ring structure, possesses higher flexibility, possibly enhancing β-tan diffusion across the cell membrane; in contrast to Sal A which bears a closed ring structure (Figure
1). In addition to the bioactive –α-methylene-γ-lactone ring present in Sal A and β-tan, the latter harbors an additional alkylating center, the cyclopentenone. Moreover, the presence of two hydroxyl (OH) groups within Sal A renders the molecule less lipophilic, possibly decreasing cell membrane penetration and may explain its reduced toxicity to JB6P + cells compared to β-tan.
In studying the anti-tumor promoting properties of these two purified SL molecules, it was essential to assess their effect on TPA-induced JB6P + cell transformation. In this study, we found that both β-tan and Sal A inhibited TPA-induced JB6P + cell transformation, at concentrations not cytotoxic to normal nor to the non-tumorigenic JB6P + cells. A hallmark of cell transformation is the ability of malignant cells to grow in soft agar in an anchorage-independent manner [
18,
23,
36]. Our results show that β-tan and Sal A, at concentrations that did not inhibit JB6P + cell proliferation, were effective in reducing TPA-induced proliferation and inhibiting TPA-induced colony formation. These results suggest that β-tan and Sal A may have promising chemopreventive properties in epidermal carcinogenesis. Future
in vivo experiments are required to confirm the chemopreventive properties of these purified SL molecules. However, a limiting step for
in vivo studies will be the availability of large quantities of these molecules.
The activation of the transcription factors AP-1 and NF-κB is essential for tumor promotion and neoplastic transformation, and are highly expressed in the promoter-sensitive JB6P + cells, and the inhibition of both or either one of these signaling pathways is sufficient to inhibit neoplastic transformation [
19,
23,
25]. To study the modulation of tumor promoter-induced AP-1 and NF-κB transcriptional activities by β-tan and Sal A in JB6P + cells, concentrations that inhibited JB6P + cell transformation and did not affect normal cell growth were used. Interestingly, both SL molecules decreased basal and TPA-induced NF-κB activities, but not of TPA-induced AP-1 activity. This suggests that β-tan and Sal A primarily inhibit NF-κB signaling in tumor cells. In fact, it is well established that NF-κB is a vital molecular target for various SL, and some of them, such as parthenolide, artimisinin and thapsigargin are currently in cancer clinical trials [
6,
9,
43]. This can be attributed to the presence of the α-methylene-γ-lactone functional group, which directly alkylates cysteine residues of the p65 subunit, interfering with DNA binding [
6,
44]. In fact, elevated NF-κB signaling is sufficient to induce epidermal tumor transformation [
27]. This prompted us to study the effect of these SL molecules on the protein levels of one of the main NF-κB inhibitors, IκBα. Previous studies have shown that the expression of non-degradable mutants of IκBα and antisense RNA inhibition of NF-κB, result in tumor regression [
29,
45‐
47]. Interestingly, only pre-treatment with β-tan restored IκBα protein levels after 15 minutes of TPA-treatment, suggesting that Sal A and β-tan differentially mediate their inhibition of NF-κB signaling. This differential regulation of IκBα proteins by the SL molecules can be attributed to their differences in alkylating centers and lipophilicity, thus, affecting their interaction with the IκBα proteins. Nevertheless, β-tan also significantly increased basal AP-1 levels in JB6P + cells at concentrations that decreased cell growth. This may implicate the dual role of AP-1 in increased cell proliferation and cell death [
48].
Since earlier studies have shown that AP-1 and NF-κB can interact together [
49], we assessed how both SL molecules modulated key downstream target genes, containing TPA response elements (TREs) common to both AP-1 and NF-κB. Metalloproteinases are essential for tumor promotion, progression, and invasion and AP-1 and NF-κB play a dominant role in the transcriptional activation of the majority of MMPs [
50,
51] including MMP-9 and MMP-2. In fact, it was shown in mice lacking MMP-9 that this gene is functionally involved in the regulation of oncogene-induced keratinocyte hyperproliferation, progression to invasive cancer, and end-stage malignant grade epithelial carcinomas [
52]. Treatment of TPA-promoted JB6P + cells with β-tan or Sal A, abrogated MMP-9, but not MMP-2, protein levels. This implies that the two SL molecules differentially modulate MMP protein levels suggesting the regulation of MMP2 by factors other than AP-1 and NF-κB.
Another important AP-1 and NF-κB target gene is the CDKI p16. Both SL molecules noticeably up regulated p16 that was reduced upon TPA treatment, which suggests that β-tan and Sal A inhibit cell cycle progression that is induced by tumor promoters. Furthermore, AP-1 and NF-κB components also regulate apoptotic proteins such as the pro-apoptotic Bax and the anti-apoptotic Bcl-2 proteins [
38,
51]. SL are known to be inducers of apoptosis in a variety of cancer cells, and this is considered one of the important mechanisms by which SL exert their anti-tumor properties [
6]. Our results show that both β-tan and Sal A increase the Bax:Bcl-2 ratios in TPA-promoted JB6P + cells and suggest that Bcl-2 family members are involved in the growth suppressive effects of β-tan and Sal A.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MS, AG and RH performed the experiments and data analysis. MS wrote the manuscript. AG provided statistical analysis and revised the manuscript. NS supervised the extraction and identification of β-tan and Sal A. SNT contributed in the identification and selection of plant species with potential medicinal properties, provided plant material for isolation and testing of molecules, and contributed to the editing of the manuscript. ND designed and oversaw the study, interpreted the data, and revised the manuscript. All authors read and approved the final manuscript.